What to treat? The structural basis for renal and vascular complications and hypertension, and the role of angiotensin converting enzyme inhibition. Symposium, 26th meeting of the European Association for the Study of Diabetes. Dublin, Ireland, 10 September 1991.
出版信息
J Hypertens Suppl. 1992 Apr;10(1):S1-53.
PMID:1619498
Abstract
摘要
相似文献
1
What to treat? The structural basis for renal and vascular complications and hypertension, and the role of angiotensin converting enzyme inhibition. Symposium, 26th meeting of the European Association for the Study of Diabetes. Dublin, Ireland, 10 September 1991.
J Hypertens Suppl. 1992 Apr;10(1):S1-53.
2
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Can J Cardiol. 2002 May;18 Suppl A:3A-6A.
3
When hypertension and diabetes coexist: strategies for cardiorenal protection.
Postgrad Med. 2000 Oct;108(5 Suppl):12-8. doi: 10.3810/pgm.10.2000.suppl8.46.
4
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Nihon Rinsho. 2002 Sep;60 Suppl 9:679-84.
5
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.
Blood Press. 2007;16(2):72-9. doi: 10.1080/08037050701338985.
6
[Angiotensin converting enzyme inhibitors or angiotensin II receptor blocker in cardiovascular and renal pathology in 2006: what does EBM teach us?].
Rev Med Liege. 2006 May-Jun;61(5-6):414-22.
7
ARBs for cardiovascular and renal protection in high-risk patients.
Cardiovasc J Afr. 2011 Jul-Aug;22(4):224.
8
Recent review highlights implications for prevention of cardiovascular disease.
Cardiovasc J S Afr. 2003 May-Jun;14(3):161-2.
9
Slowing progression along the renal disease continuum.
J Am Osteopath Assoc. 2005 Apr;105(4):207-15.
10
ACE inhibition in cardiovascular disease.
N Engl J Med. 2000 Jan 20;342(3):201-2. doi: 10.1056/NEJM200001203420309.
Zotero 插件